Use of molnupiravir: A Danish nationwide drug utilization study

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

13 Downloads (Pure)


Purpose: To describe utilization patterns, characteristics of users and prescribers of the new oral antiviral medication, molnupiravir, indicated for mild-to-moderate COVID-19. Methods: Using nationwide registries, we identified all Danish adults who filled a prescription for molnupiravir from December 16th, 2021, to August 31st, 2022. We described weekly incidence rates and patient characteristics over time, prescriber characteristics as well as time between molnupiravir initiation and a positive SARs-CoV-2 test. Patient characteristics were compared to matched, untreated SARS-CoV-2 positive reference groups. Results: By August 31st, 2022, 5847 individuals had filled a prescription for molnupiravir. The incidence rate gradually increased to 16 weekly prescriptions per 1000 RT-PCR SARS-CoV-2 positives. Users of molnupiravir were most often men (55% vs. 45% women). The majority (81%) had a positive RT-PCR SARS-CoV-2 test and few (2.9%) redeemed molnupiravir outside the recommended window of 5 days from the positive test result. Compared to matched, untreated SARS-CoV-2 positive reference groups, users of molnupiravir had a median age of 74 years versus 49 years, a higher proportion resided in a nursing home (12% vs. 1.5%) and had a higher number of comorbidities (median of 3 vs. 0); most commonly hypertension (38%), chronic lung disease (35%), diabetes (20%) and mood disorders (20%). General practitioners were the primary prescribers of molnupiravir (91%). Conclusions: Molnupiravir was mainly prescribed by general practitioners to RT-PCR SARS-CoV-2 positive individuals who had a potentially increased risk of severe COVID-19. Though some off-label prescribing occurred, our study indicates a high level of adherence to contemporary guidelines.

TidsskriftPharmacoepidemiology and Drug Safety
Udgave nummer1
Antal sider6
StatusUdgivet - jan. 2024

Bibliografisk note

Funding Information:
Lotte Rasmussen reports participation in research projects funded by Novo Nordisk outside the current work. Peter Bjødstrup Jensen, Jesper Hallas and Mette Reilev report participation in research projects funded by Leo Pharma A/S outside the current work. Louise Ladebo, Anne Øvrehus and Mette Lindahl report no conflict of interests.


Dyk ned i forskningsemnerne om 'Use of molnupiravir: A Danish nationwide drug utilization study'. Sammen danner de et unikt fingeraftryk.